Growth opportunities Avion is a specialty pharma with a growing portfolio across Women’s Health, Dermatology, Hematology and related Specialties, presenting opportunities to cross-sell branded prescription products and dietary supplements to existing channels and healthcare providers.

Boutique scale advantage With 51-200 employees and revenue in the 25-50 million range, Avion operates leanly, suggesting agility in negotiating licenses, partnerships, and co-development deals with larger players to expand market reach efficiently.

Recent launches Recent product introductions such as Prenate Chewable and Dhivy indicate active product development and a willingness to pursue new therapeutic areas, signaling readiness to collaborate on distribution, regulatory support, and market access.

Strategic alliances Past partnerships and licensing with Aspen Pharma and ImmuPharma for estrogen therapy and Lupus treatment highlight a track record of collaboration; this points to potential for new licensing, co-promotion, or in-licensing opportunities with AVION’s portfolio.

Technology and data readiness Adoption of analytics and enterprise systems (Power BI, Tableau, SAP, SQL Server, Dynamics) supports data-driven sales and market access strategies, enabling targeted physician outreach, payer negotiations, and performance analytics to optimize partnerships.